NCT00485017 - Efficacy and Safety of THR-4109 in Obese Subjects | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Obesity

Interventions

DRUG

THR-4109

THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks

DRUG

Placebo

Oral capsules daily in a.m. and in p.m. for 24 weeks

Trial Locations (20)

107014

Investigational Site #61, Moscow

117036

Investigational Site #51, Moscow

121069

Investigational Site #60, Moscow

123056

Investigational Site #57, Moscow

125315

Investigational Site #50, Moscow

129010

Investigational Site #54, Moscow

163045

Investigational Site #62, Arkhangelsk

192283

Investigational Site #63, Saint Petersburg

194291

Investigational Site #67, Saint Petersburg

194354

Investigational Site #53, Saint Petersburg

Investigational Site #66, Saint Petersburg

195267

Investigational Site #59, Saint Petersburg

197110

Investigational Site #65, Saint Petersburg

197198

Investigational Site #55, Saint Petersburg

198134

Investigational Site #58, Saint Petersburg

199178

Investigational Site #64, Saint Petersburg

410018

Investigational Site #56, Saratov

SE-240 10

Investigational Site #12, Dalby

SE-411 36

Investigational Site #11, Gothenburg

SE-205 02

Investigational Site #13, Malmo